Skip to main content Skip to accessibility
This website is not compatible with your web browser. You should install a newer browser. If you live in Jersey and need help upgrading call the States of Jersey web team on 440099.
Government of Jerseygov.je

Information and public services for the Island of Jersey

L'înformâtion et les sèrvices publyis pouor I'Île dé Jèrri

Prescribed List: Changes from 1 June 2015

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

  • demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision

  • providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made 1 May 2015:

Decision Reference: MD-S-2015-0036

Decision Summary Title :

Prescribed List Changes 1 June 2015

Date of Decision Summary:

27 April 2015

Decision Summary Author:

Prescribing Advisor

Decision Summary:

Public or Exempt?

Public

Type of Report:

Oral or Written?

Written

Person Giving

Oral Report:

N/A

Written Report

Title :

Changes to be made to the Prescribed List as at 1 June 2015

Date of Written Report:

21 April 2015

Written Report Author:

Prescribing Advisor

Written Report :

Public or Exempt?

Exemption: FoI (J) Law 2011  Part 5 (33) Commercial Interests

Subject:

Changes to be made to the Prescribed List (Jersey) as at 1 June 2015

Decision(s): Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List.

The Minister added three new medicinal products :

  • Glycopyrronium bromide 50 micrograms capsules for inhalation via the Seebri Breezhaler device for the treatment of chronic obstructive pulmonary disease (COPD)
  • Indacaterol maleate 110 mcg/glycopyrronium bromide 50mcg capsules for inhalation via the Ultibro Breezhaler device for the treatment of chronic obstructive pulmonary disease (COPD)
  • Tamsulosin hydrochloride 400 micrograms, solifenacin succinate 6 mg modified release tablets for the treatment of moderate to severe urinary frequency, urgency, and obstructive symptoms associated with benign prostatic hyperplasia when monotherapy is ineffective

 

In addition, the Minister approved minor amendments to allow the following additional strengths of products to be added to existing entries in the Prescribed List:

  • Dexamethasone injection 3.3mg/mL
  • Aripiprazole tablet 5mg
  • Prucalopride tablet 2mg
  • Galantamine capsule 8mg
  • Hydralazine tablet 50mg

 

The Minister also supported the switch to generic only reimbursement for the following branded products:

  • Movicol/Laxido
  • Cerazette
  • Zithromax capsules

 

The Minister approved removal of the following products from the Prescribed List

  • Azithromycin capsules 250mg (to be replaced by azithromycin tablets 250mg, 500mg)
  • Cefalexin tablet 250mg, 500mg
  • Squill opiate mixture
  • Ethinyloestradiol tablets 10mcg, 50mcg, 1mg

 

 

Additions to the Prescribed List will be effective from 1 June 2015. Where items are to be removed from the List or to be Listed by generic name only, this will be effective from the 1 June 2015 listing but prescriptions for these products will be reimbursed until 31 August 2015.

 

Reason(s) for Decision:

The Pharmaceutical Benefit Advisory Committee (PBAC) met on 14 April 2015 and has provided the Minister with the accompanying written report setting out its recommendations in respect of amendments to the Prescribed List.

 

The changes reflect current evidence and expert advice, and ensure that patients in Jersey have access to an appropriate range of modern, safe and effective treatments from their GPs at a proportionate cost to the Fund.

Resource Implications:

The overall impact of the changes represents an anticipated reduction in expenditure from the Fund of around £120,000 per annum.

Action required:

Policy Principal to issue public notice listing amendments and notify all approved medical practitioners and approved contractors.

 

Signature:

Position:

Minister

Date Signed:

 

Date of Decision (If different from Date Signed):

 

Back to top
rating button